N/A N=16 Jowl Improvement With Injectable Fillers
Jowls
Primary: Blinded Physician Jawline Rating Scale (JRS) Assessment on Scale of 0 to 4 at Baseline Versus 4 Weeks After Last Injection. — 2.214; 2.071; 1.857; 1.857 score on a scale…
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
N/A N=15 Cryolipolysis for Jawline Contouring
Body Fat Disorder
Primary: Number of Participants With Unanticipated Adverse Device Effects (UADE) — 0 Participants with UADE reported
N/A N=32 Lifting and Tightening of the Face and Neck Following an Increased Density Treatment
Skin Laxity
Primary: Improvement in Overall Lifting and Tightening of Skin — 48 percentage of participants improved
Phase 4 N=58 Sequential Treatment With BELKYRA® Then Juvéderm® VOLUMA™ With Lidocaine for Overall Improvement in Jawline Contour
Contour
Primary: Percentage of Participants Who Showed ≥ 1-point Jawline Improvement From Baseline on the Allergan Loss of Jawline Definition Scale (ALJDS), as Assessed by the…
Phase 3 N=206 Study of the Safety and Effectiveness of JUVÉDERM VOLUX™ XC Injectable Gel for Restoring Jawline Definition
Jawline Definition
Primary: Percentage of Participants Who Show ≥ 1-point Jawline Improvement on Both Sides From Baseline on the Allergan Loss of Jawline Definition Scale (ALJDS) — 38.0; 69.0…
N/A N=140 Effectiveness and Safety of Restylane Lyft Lidocaine for Jawline Definition
Jawline Definition
Primary: Percentage of Responders Having At Least a 1-Grade Improvement From Baseline on Both Jawlines Concurrently Based on Galderma Jawline Scale (GJS) at Month 3 as Assessed…
N/A N=180 Evaluation of Effectiveness and Safety of Radiesse (+) to Improve the Contour of Jawline by Adding Volume to the Jawline
Improvement of Jawline Contour
Primary: Responder Rate According to the Merz Jawline Assessment Scale (MJAS) — 75.6; 8.8 percentage of participants — p=<0.0001
N/A N=224 To Evaluate Effectiveness and Safety of GP0109 for Jawline Definition
Jawline Definition Deficiency
Primary: Percentage of Responders Based on Blinded Evaluators' Live Assessment of the Galderma Jawline Scale (GJS) — 14.3; 85.1 percentage of participants — p=<0.001
N/A N=60 Subcutaneous Fat Reduction in the Submental Area
Body Fat Disorder
Primary: Safety of CoolScupting in the Submental Area — 4 incidence of device- and/or procedure AE
N/A N=103 Evaluation of the Ulthera™ System for Obtaining Lift and Tightening of the Cheek Tissue
Mild to Moderate Skin Laxity on Cheek · Mild to Moderate Skin Laxity on Upper Neck · Mild to Moderate Subcutaneous Fat on Cheek
Primary: Change in Overall Lifting and Tightening of Treated Tissue on the Lower Face and Submental Regions. — 68.60 percentage of participants improved
N/A N=60 Open-label, Prospective Evaluation of the Ulthera® System for Lifting Submental (Under the Chin) and Neck Tissue in Chinese Patients
Mild to Moderate Skin Laxity Under the Chin · Mild to Moderate Skin Laxity on Neck
Primary: Mean Change From Baseline in Overall Lifting and Tightening of Submental (Under the Chin) and Neck Tissue Area at Day 90 Post-treatment — -14.4; -7.9; -22.3 square…
N/A N=29 Evaluation of the MJGS Following Radiesse (+) Injection Into the Jawline
Volume Loss of the Jawline
Primary: Percentage of Jawlines Achieving Greater Than or Equal to (>=) 1-point Improvement on Merz Jawline Grading Scale (MJGS) at Week 4 — 92.1; 0; 92.1; 0 percentage of…
N/A N=82 Renuvion APR Device to Improve the Appearance of Lax Tissue in the Neck and Submental Region
Lax Skin
Primary: Day 180 Number of Participants With Improvement Measured By Independent Photographic Review — 6; 52 Participants — p=<0.0001
N/A N=148 Restylane Defyne for Correction of Chin Retrusion
Chin Retrusion
Primary: Percentage of Participants (Responders) With At Least 1-Point Improvement From Baseline on the GCRS, as Assessed by the Blinded Evaluator at Month 6 ([Baseline…
N/A N=201 Reliability of a Masseter Muscle Prominence Scale and Lower Facial Shape Classification
Healthy Volunteers
Primary: Inter-rater Reliability Using a Masseter Muscle Prominence Scale (MMPS) — 0.728; 0.711 Kendall's W
Phase 4 N=16 Submental Study (Sequential Treatment Approach)
Body Fat Disorder
Primary: The Proportion of Subjects Who Have at Least a 1-grade Improvement on the Clinician Reported Submental Fat Rating Scale (CR-SMFRS) at the Final Follow-up Visit When…
Phase 3 N=165 Open-Label Study of Deoxycholic Acid for the Reduction of Localized Subcutaneous Fat in the Submental Area
Moderate or Severe Submental Fullness
Primary: Number of Participants With Adverse Events (AEs) — 160; 7; 11; 15 participants